Study of DEC003M for advanced prostate cancer
Part of Cancer clinical trials.
This trial tests a new targeted therapy (DEC003M) for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to see if this treatment is safe and helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have been diagnosed with prostate cancer (adenocarcinoma).
- Your cancer has spread to other parts of the body and no longer responds to hormone therapy (it is still growing).
- You have already tried at least one treatment that blocks the androgen receptor pathway (such as enzalutamide or abiraterone).
- You are able to take care of yourself and do most daily activities (ECOG score 0 or 1).
- You have not had other cancers, active autoimmune diseases, serious heart or lung conditions, or treatments that affect your eyes or nerves.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests a combination of two experimental drugs, HS-20093 and HRS-5041, for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if this new treatment can help control the cancer when other treatments have stopped working.
This trial tests an experimental drug, GLR2037, for men with advanced prostate cancer that has spread to the bones or soft tissue and has progressed despite prior treatments. The drug may help slow the cancer's growth.
This early-stage trial tests a new drug called TRC003 for men with advanced prostate cancer that has spread and stopped responding to standard treatments. The drug is designed to target cancer cells that show a specific marker called PSMA.
This study tests a new investigational medicine for prostate cancer that has spread and is no longer controlled by standard hormone therapy. The drug may work by targeting a protein on cancer cells, and the trial will check if it can shrink the cancer or slow its growth.
This study tests two new drugs, regn21353 and nezastomig, alone or together, in men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if these drugs can help slow the cancer's growth.
Hear when a new Advanced Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.